



Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer

Zhipeng Wang^{1#}, Haoyang Liu^{1#}, Jinge Zhao^{1#}, Junru Chen¹, Sha Zhu¹, Jindong Dai¹, Yuchao Ni¹, Nanwei Xu¹, Fengnian Zhao¹, Ben He^{1,2}, Xingming Zhang¹, Jiayu Liang¹, Guangxi Sun¹, Zhenhua Liu¹, Pengfei Shen¹, Hao Zeng¹

¹Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China; ²Department of Urology, The Third People's Hospital of Chengdu, Chengdu, China

#These authors contributed equally to this work.

Correspondence to: Prof. Pengfei Shen; Prof. Hao Zeng. Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. Email: cdhx510@foxmail.com; kucaizeng@163.com.

Submitted Mar 22, 2023. Accepted for publication Mar 30, 2023. Published online Apr 12, 2023.

doi: 10.21037/atm-2023-7

View this article at: <https://dx.doi.org/10.21037/atm-2023-7>

Retraction to: *Ann Transl Med* 2023;11:201

The paper “The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer” (doi: 10.21037/atm-22-4318) published in *Annals of Translational Medicine* in Vol 10, No 5 (March 15, 2023) (1) has been retracted at the request of the authors. All authors agree with the retraction of the paper. We hereby declare.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-2023-7/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Wang Z, Liu H, Zhao J, et al. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer. *Ann Transl Med* 2023;11:201.

Cite this article as: Wang Z, Liu H, Zhao J, Chen J, Zhu S, Dai J, Ni Y, Xu N, Zhao F, He B, Zhang X, Liang J, Sun G, Liu Z, Shen P, Zeng H. Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer. *Ann Transl Med* 2023;11(9):332. doi: 10.21037/atm-2023-7